Plunkett Research Online: Cyclerion Therapeutics Inc

CYCLERION THERAPEUTICS INC (CYCN:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.Its focus is on enabling the full therapeutic potential of next.....



Cyclerion Therapeutics Inc
Ticker: CYCN
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617 621-7722
Fax:
Address: 301 Binney Street
Cambridge, MA 02142 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
ContactsDescription

Peter HechtCEO/Director
William HuyettCFO
See More
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.Its focus is on enabling the full therapeutic potential of next.....See More See More

Auditor: Ernst & Young LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: